Browse the evidence

Obesity in IBD patients is associated with altered pharmacokinetics of biological therapies, leading to faster drug clearance, lower trough concentrations, and potentially reduced treatment efficacy.

If you take biological injections for IBD and are obese, your body might process the drug faster than a lean person's, making it less effective. You should discuss this with your doctor. They might monitor your drug levels more closely or adjust your dose to ensure you get the full benefit of the treatment.

Semaglutide (2.4 mg once weekly) promotes adipose tissue browning and mitochondrial biogenesis via the AMPK/SIRT1/PGC1α/UCP1 axis, enhancing energy expenditure and thermogenesis, although this mechanism is primarily established in preclinical rodent models rather than confirmed in humans.

Semaglutide 2.4mg weekly leads to ~15% weight loss. While it likely works partly by boosting metabolism (browning fat) via complex hormonal pathways seen in animals, the primary driver for you is reduced appetite. Do not rely on the 'browning' mechanism to explain your results; focus on the proven appetite suppression.

Dual and triple incretin receptor agonists (e.g., tirzepatide, retatrutide) show potential for greater cardiovascular risk factor reduction than single GLP-1RAs, though definitive cardiovascular outcome trial results are pending.

Newer multi-incretin agonists (like tirzepatide) are showing superior improvements in blood sugar, weight, and blood pressure compared to single GLP-1RAs. While their specific impact on heart attacks and strokes is still being studied, they represent a promising next step for cardiovascular risk reduction in diabetes.

Resistance exercise-induced lactate accumulation may promote skeletal muscle hypertrophy through multiple mechanisms including lactate-stimulated testosterone production, histone lactylation, and activation of satellite cell pathways via GPR81/ERK1/2 signaling, although direct evidence in humans is currently insufficient.

While mechanical tension is king, incorporating training styles that generate high lactate (e.g., higher reps, shorter rest) may offer additional hypertrophic benefits via metabolic signaling. However, do not rely on this as a primary driver, as human evidence is currently weak compared to mechanical load.

A single-administration self-boosting microneedle patch delivering semaglutide sustains therapeutic plasma levels and induces weight loss in rats for one month, effectively simulating four separate weekly subcutaneous injections.

This research proposes a microneedle patch that delivers semaglutide (a weight-loss drug) through the skin. Instead of getting a shot every week, you apply a small patch once, and it releases the medication slowly over four weeks. In rats, this worked just as well as getting four separate shots. While promising for reducing pain and improving adherence, this is still experimental technology tested only on animals, not yet available for human use.

Precision nutrition strategies, including monitoring postprandial glycemic responses and gut microbiome composition, may attenuate unfavorable cardiovascular risk factors associated with menopause.

Consider how your body responds to specific foods after eating (postprandial response). While full precision nutrition testing may not be available, focusing on fiber, reducing sugar, and potentially incorporating isoflavone-rich foods (like soy) may support gut health and metabolic stability during menopause.

GLP-1 agonist administration in Type 1 Diabetes patients can precipitate Euglycemic Diabetic Ketoacidosis (EDKA) by suppressing gluconeogenesis and glycogenolysis, masking the hyperglycemia typically required for DKA diagnosis.

If you have Type 1 Diabetes and are taking a GLP-1 agonist (like Wegovy or Ozempic), be aware that you can develop Diabetic Ketoacidosis (DKA) even if your blood sugar looks normal. This is called Euglycemic DKA. If you experience nausea, vomiting, or abdominal pain, do not assume it is just a side effect or that your insulin is working. Check your blood ketones and seek medical attention if they are elevated, as standard DKA treatments (high insulin, no dextrose) may be dangerous without dextrose support.

Chronic stimulation of pancreatic beta-cells by incretin agonists may lead to beta-cell exhaustion, receptor downregulation, and potentially beta-cell failure over the long term.

While generally safe, long-term use of incretin medications may theoretically stress pancreatic beta-cells. Doctors monitor for this, but the long-term human data is still being gathered. It is important to discuss any concerns about long-term safety with your healthcare provider.

Chronic GIPR agonism may lead to desensitization that mimics functional antagonism, potentially explaining why both agonists and antagonists result in weight loss.

There is a theoretical possibility that long-term use of GIP-activating drugs could lead to receptor desensitization, acting like a blocker. However, current clinical evidence does not strongly support this in the brain, and these drugs remain effective for weight loss. Monitor your progress with your doctor.

Unimolecular tetra-receptor agonists (TC4) simultaneously activate GLP-1R, GIPR, GcgR, and Y2R, resulting in superior metabolic efficacy (weight loss and glycemic control) compared to mono- or dual-agonists by leveraging synergistic receptor engagement.

This research describes a new class of peptide drugs that target four metabolic receptors (GLP-1, GIP, Glucagon, and PYY) simultaneously. In preclinical studies, this approach showed strong potential for treating obesity and type 2 diabetes with fewer side effects like nausea than older drugs. It is not yet available for human use.

Tirzepatide administration is associated with novel postmarketing adverse events including palpitations, musculoskeletal pain, and headaches, which were not prominent in initial clinical trials.

If you experience palpitations, muscle pain, or headaches after starting Tirzepatide, report these to your doctor. These are not the typical stomach issues and may require dose adjustment or injection site changes.

Tirzepatide, a dual GLP-1/GIP receptor agonist, may modify the natural course of lipedema by targeting its underlying immunometabolic, inflammatory, and fibrotic pathophysiology, rather than solely reducing body weight.

If you have lipedema, especially with insulin resistance, talk to your doctor about tirzepatide. It’s not just for weight loss; it may help reduce the inflammation and fibrosis causing your pain and stiffness. Since it’s a newer treatment for lipedema, ask about clinical trials or off-label use if appropriate for your case.

Heterozygous variants in the POMC gene (specifically p.Arg90His, p.Ser94Gly, p.Ser94=, and p.Ala195=) are associated with an intermediate obesity phenotype in adults, likely due to haploinsufficiency affecting melanocortin peptide processing.

If you carry a heterozygous POMC variant, you may have an intermediate form of genetic obesity that responds differently to standard interventions. This information can help tailor your treatment plan, though functional validation of specific variants is still needed.

Tirzepatide as an adjunct to insulin in adults with Type 1 Diabetes and overweight/obesity produces significant body weight reduction and reduced insulin requirements, but current evidence is insufficient to establish durable glycaemic benefit or long-term safety.

For adults with Type 1 Diabetes and obesity, Tirzepatide is a promising tool for significant weight loss and reducing insulin needs. However, it is not yet proven to reliably improve long-term blood sugar control or safety. If used, it requires careful monitoring for side effects like nausea and potential risks like DKA, especially if insulin is reduced too aggressively. It is currently an investigational option, not a standard of care.

BPC-157 accelerates tissue repair (tendons, muscles, ligaments, GI mucosa) by stimulating angiogenesis and modulating inflammation, though it lacks FDA approval and robust human clinical trials.

BPC-157 is a peptide studied for its ability to speed up the healing of tendons, muscles, and gut lining. While animal studies show promising results for tissue repair, it is not yet approved by the FDA for human use. It is sometimes used off-label in sports medicine, but robust human clinical trials are still needed to confirm its safety and efficacy.

Intermittent fasting does not significantly improve cardiovascular risk factors (lipid profile, blood pressure) or diabetes markers (HbA1c, fasting glucose) compared to daily caloric restriction.

Do not expect intermittent fasting to fix your cholesterol or blood sugar better than a standard calorie-restricted diet. The primary benefit is weight loss, which may indirectly help these markers, but the fasting pattern itself offers no superior advantage for cardiovascular or diabetes risk factors.

Menstrual cycle phase has a trivial effect on exercise performance in eumenorrheic women, with no evidence supporting general guidelines for modulating training across phases.

Stop tracking your menstrual cycle to schedule workouts. The science shows that performance differences across phases are trivial and inconsistent. Instead of trying to align your training with your hormones, focus on consistent training habits. If you notice a personal pattern where you feel weaker or stronger in a specific phase, adjust your expectations for that specific session, but do not change your overall training plan based on the calendar.

SGLT-2 inhibitors increase the risk of genital infections, while GLP-1 receptor agonists may increase the risk of severe gastrointestinal events.

Be aware of potential side effects: SGLT-2 inhibitors can increase genital yeast infections, and GLP-1 agonists can cause nausea or GI issues. These are common and manageable, but you should discuss prevention strategies (like hygiene for SGLT-2 or slow dose titration for GLP-1) with your doctor before starting.

Lifestyle interventions may improve the Free Androgen Index (FAI) in women with PCOS, but evidence quality is low.

Lifestyle changes may help lower male hormone levels (FAI) in women with PCOS. However, the evidence is not strong enough to be certain, so this should be viewed as a potential benefit rather than a guaranteed outcome.

Accelerated gastric emptying in overweight and obese individuals may contribute to rapid postprandial glucose increases and insulin resistance.

For those with obesity, managing gastric emptying through dietary choices (e.g., fiber) might help stabilize blood sugar. However, more research is needed to confirm this link.

Pharmacological activation of the Nrf2 pathway using small molecule activators (e.g., Bardoxolone methyl, Sulforaphane) shows promise in improving renal function and metabolic indices in animal models, but human trials have shown mixed results with potential cardiovascular risks.

Be cautious with unapproved Nrf2-activating drugs like Bardoxolone methyl. While they showed promise in early trials for kidney function, a later large trial was stopped due to heart-related risks. Do not self-medicate with experimental compounds. Stick to natural dietary sources of Nrf2 activators (like cruciferous vegetables) which are generally safe.

Specific probiotic strains (e.g., Bifidobacterium pseudocatenulatum CECT 7765) can reduce stress-induced corticosterone levels and improve depressive-like behavior in obese animal models by modulating the gut microbiota.

This specific probiotic strain showed promise in reducing stress hormones in obese mice. While human results are not guaranteed, it suggests that targeted probiotic supplementation might be worth exploring for stress and mood management in obesity, alongside diet changes.

Gut microbiota modulate appetite by influencing the metabolism of Tryptophan (Trp) into serotonin (5-HT) and indole derivatives, which regulate satiety and intestinal permeability.

Tryptophan metabolism by gut bacteria influences serotonin levels, which affect appetite. However, because results are inconsistent and depend on dosage and health status, focus on whole-food sources of tryptophan (e.g., turkey, eggs, seeds) rather than high-dose supplements for appetite control.

Combined diet and exercise interventions during pregnancy do not clearly reduce the risk of pre-eclampsia compared to standard care.

While combining diet and exercise during pregnancy is beneficial for preventing gestational diabetes and may help with caesarean section rates, current evidence does not show it clearly prevents pre-eclampsia. Continue to follow your healthcare provider's advice for managing blood pressure and other pregnancy risks.